insulin NPH · Humulin N

Peptide

Approved / Phase 4Insulin receptorNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Type 1 Diabetes
NCT00184665 · Novo Nordisk A/S
2004-06 – 2006-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00605137 · Novo Nordisk A/S
2004-05-21 – 2005-04-23 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00046501 · Sanofi
2002-11 – 2005-02 · Diabetes Mellitus
What this study did
NCT00725036 · Novo Nordisk A/S
2002-09-02 – 2004-12-14 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00595374 · Novo Nordisk A/S
2003-12-02 – 2004-10-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312156 · Novo Nordisk A/S
2002-08 – 2003-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00832182 · Novo Nordisk A/S
1999-12-22 – 2002-11-25 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01707134 · Novo Nordisk A/S
1997-09 – 2000-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT06619301 · Loyola University
2024-04-01 – 2027-01-01 · Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
What this study did
NCT00383877 · Novo Nordisk A/S
2006-09 – 2007-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00504673 · Novo Nordisk A/S
2005-04 – 2006-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00104182 · Novo Nordisk A/S
2005-02 – 2006-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00604253 · Novo Nordisk A/S
2003-12 – 2005-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00600626 · Novo Nordisk A/S
2004-01 – 2004-07 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00604396 · Novo Nordisk A/S
2003-03 – 2004-01 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00604344 · Novo Nordisk A/S
2003-04 – 2005-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00065130 · Novo Nordisk A/S
2000-04 – 2003-12 · Diabetes, Gestational Diabetes
What this study did
Phase 1 (3)
Type 1 Diabetes
NCT01542450 · Novo Nordisk A/S
2002-08 – 2003-02 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01497600 · Novo Nordisk A/S
2004-02 – 2004-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00760448 · Novo Nordisk A/S
2004-04 – 2005-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 4 (9)
Type 1 Diabetes
NCT00509925 · Novo Nordisk A/S
2007-07 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00313742 · Novo Nordisk A/S
2006-04 – 2006-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00597233 · Novo Nordisk A/S
2002-10 – 2002-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01832935 · Tehran University of Medical Sciences
2011-07 – 2012-07 · Type 2 Diabetes Mellitus
What this study did
NCT00121966 · Odense University Hospital
2003-01 – 2007-07 · Type 2 Diabetes Mellitus
What this study did
NCT00494988 · Novo Nordisk A/S
2004-12 – 2006-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00593255 · Novo Nordisk A/S
2004-07 – 2005-04 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT00799448 · Novo Nordisk A/S
2003-09-16 – 2004-09-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03511521 · Northwestern University
2018-03-27 – 2019-08-15 · Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
What this study did
Early phase / not applicable (4)
Type 1 Diabetes
NCT00626080 · Amsterdam UMC, location VUmc
2009-01 – 2011-12 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT01837680 · St. Luke's-Roosevelt Hospital Center
2013-03 – 2015-03 · Diabetes, Gestational, Diabetes, Type 2
What this study did
NCT00147836 · Sun Yat-sen University
2004-09 – 2007-10 · Type 2 Diabetes Mellitus
What this study did
Used as active comparator (13)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (5)
Type 1 Diabetes
NCT00435019 · Novo Nordisk A/S
2007-02 – 2008-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01697657 · Novo Nordisk A/S
2001-09 – 2002-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01486940 · Novo Nordisk A/S
2002-03 – 2002-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01790438 · Eli Lilly and Company
2013-03 – 2014-05 · Diabetes Mellitus, Type 2
What this study did
NCT00783744 · Sanofi
2001-12 – 2003-08 · Diabetes Mellitus, Type 2
What this study did
Phase 2 (2)
Type 2 Diabetes
NCT05124457 · University of California, Los Angeles
2022-02-01 – 2025-06 · Gestational Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00660374 · Novo Nordisk A/S
2008-02 – 2009-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 1 (1)
Type 2 Diabetes
NCT01497561 · Novo Nordisk A/S
2003-03 – 2003-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 4 (4)
Type 1 Diabetes
NCT05768191 · Université NAZI BONI
2023-06-15 – 2024-05-01 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT00795600 · Novo Nordisk A/S
2009-04 – 2010-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00506662 · Novo Nordisk A/S
2007-07 – 2008-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Early phase / not applicable (1)
Type 1 Diabetes
NCT00522210 · University of Calgary
2008-03 – 2011-03 · Type 1 Diabetes
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Type 2 Diabetes
NCT01562561 · Novo Nordisk A/S
2001-06-01 – 2002-12-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin NPH (Humulin N): this drugApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.